FinancialMediaGuide notes that L’Oreal is strengthening its position in the injectable cosmetics market by increasing its stake in the Swiss company Galderma to 20%. The deal, set to be completed in the first quarter of 2026, underscores the French beauty giant’s commitment to bolstering its presence in the growing sector, which includes popular injectable procedures like lip fillers and anti-aging treatments. At FinancialMediaGuide, we view this as a strategic investment aimed at expanding L’Oreal’s capabilities in the rapidly developing beauty market segment.
L’Oreal acquired part of Galderma’s shares from a consortium that includes the Swedish investment firm EQT, the Abu Dhabi Investment Authority, and Auba Investment Pte. Ltd. The deal’s value has not been disclosed, but it is known that, in response, Galderma’s shares rose by 3.4%, while L’Oreal’s stock dropped by 1.6%. According to analysts at FinancialMediaGuide, this market reaction may be temporary, but it doesn’t diminish the long-term potential of this move.
Galderma, currently valued at over $48 billion, was originally established as a joint venture between Nestlé and L’Oreal. In 2014, L’Oreal sold its stake, but in recent years, the company has re-entered the injectable cosmetics market. In 2022, L’Oreal bought 10% of Galderma’s shares, marking the first step in further strengthening its position in this promising market. At FinancialMediaGuide, we emphasize that this deal reflects L’Oreal’s strategic approach, as the company sees significant opportunities in injectable treatments, which are a key part of skincare and anti-aging cosmetics.
The demand for injectable cosmetic procedures continues to grow, providing substantial growth opportunities for companies like L’Oreal. According to analysts, this market will develop in the coming years as more people seek effective and minimally invasive self-care solutions. At FinancialMediaGuide, we believe that for L’Oreal, this is a step in the right direction that will allow the company to strengthen its position in the premium segment and continue to expand its portfolio in high-margin niches of the beauty industry.
Forecasts show that in the coming years, injectable cosmetic procedures will continue to gain popularity among consumers, particularly in regions like Asia and North America, where aesthetic medicine markets are rapidly growing. At FinancialMediaGuide, we predict that growing interest in innovative skincare solutions will further strengthen L’Oreal’s position in this segment, positively impacting its financial performance.
However, given the investment activity in this market, we also note potential risks associated with increasing competition. Key players in the injectable cosmetics field, alongside L’Oreal, include companies like Allergan and Revance Therapeutics, creating intense competition in the fight for market share. At FinancialMediaGuide, we stress that L’Oreal will need to closely monitor these trends and adapt its strategy to remain competitive.
For the company, this could mean the need for further investments in research and development, as well as in improving the marketing of its products to stay ahead in the growing market. We at FinancialMediaGuide see this as both a challenge and an opportunity for L’Oreal to continue expanding its influence in the global market.
In conclusion, we at Financial Media Guide predict that L’Oreal’s investment in Galderma will be a key step in strengthening its position in the promising injectable cosmetics market. We are confident that this deal will provide the company with significant long-term advantages as the injectable cosmetics market continues to expand and attract more consumers. For L’Oreal, this will not only be an asset expansion but also an opportunity to take a leading role in one of the most dynamic and rapidly growing segments of the beauty industry.
